2-(2-AMINOTHIAZOL-4-YL)ACETICACIDHCL，2-(2-aminothiazol-4-yl)aceticacid, hydrochloide; ATA HYDROCHLORIDE
CAS:66659-20-9
Chemical Formula:C5H7ClN2O2S
MW:194.64
Availability: R&D; Commercialization
⬤ CAS No.66659-20-9
⬤ Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| English name | 2-(2-Aminothiazol-4-yl) acetic acid hydrochloride |
| CAS No. | 66659-20-9 |
| Chemical formula | C5H7ClN2O2S |
| Molecular weight | 194.64 |
| Related categories | Pharmaceutical intermediates; Chemical raw materials;Intermediates; Raw materials; Chemical raw materials; Impurity reference substances; Organic acids; (intermediate of cefotiam); Pharmaceutical raw materials; Pharmaceutical raw material intermediates |
| Mol | 66659-20-9.mol |
| EINECS | 1308068-626-2 |
| Melting point | 152°C |
| Storage conditions | under inert gas (nitrogen or Argon) at 2-8°C |
| Solubility | Slightly soluble in methanol |
| form | solid |
| color | White to off-white |
| CAS | 66659-20-9 |
| Customs Tariff Code | 2934100090 |
| RTECS Number | YQ1509000 |
| GHS Hazard Pictograms | GHS07 |
| Signal Word | Warning |
| Hazard Statements | H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation) |
| Physical State | White to off-white crystalline powder |
| Storage Conditions | Inert atmosphere, 2-8°C (In an inert gas environment, at 2-8°C) |
| Solubility | Slightly soluble in methanol |
| Precautionary Statements | It is recommended to avoid inhaling dust, wear protective respirators, and take appropriate first aid measures immediately if accidentally inhaled or contact with eyes. |
| Storage conditions | Should be stored in a dry, well-ventilated place, away from direct sunlight and high temperatures. |
| Use |
1. Mainly used as organic raw materials and pharmaceutical intermediates. 2. Used in the synthesis of antibiotics such as cefotiam. 3. Plays an important role in chemical synthesis and drug development. |
Exceptional Product Quality
“We have been sourcing pharmaceuticals from Tianming Pharmaceutical for several years now, and their product quality has consistently exceeded our expectations. Each batch undergoes rigorous testing, ensuring we receive only the highest quality products. This reliability has significantly contributed to our trust and satisfaction with their services. Highly recommended!”
June 15, 2023
Outstanding Technical Guidance
“The technical guidance provided by Tianming Pharmaceutical’s team has been invaluable to our research and development projects. Their experts are knowledgeable, responsive, and always willing to assist with detailed explanations and support. Their guidance has enabled us to optimize our processes and achieve remarkable results. We couldn’t ask for a better partner.”
June 15, 2023
Superior Service Experience
“Our experience with Tianming Pharmaceutical has been nothing short of excellent. Their customer service team is exceptionally responsive and dedicated to meeting our needs. From initial consultation to after-sales support, they have provided seamless, professional service. Their commitment to customer satisfaction is truly commendable.”
June 15, 2023
Precise Product Specifications
“Tianming Pharmaceutical has impressed us with their adherence to precise product specifications. Each order is meticulously packaged and delivered exactly as requested, ensuring that we receive products that perfectly meet our requirements. Their attention to detail and commitment to accuracy have made them a trusted supplier for our business.”
June 15, 2023
Regulatory differences between API and intermediate manufacturing under ICH Q7, FDA, EMA, and NMPA. GMP boundaries, DMF filing, starting material justification.
Finerenone drug class: third‑generation non‑steroidal MRA. Compare selectivity, potency, half‑life, and safety vs spironolactone/eplerenone. FDA‑approved for CKD+T2D and HF with LVEF ≥40%.
Finerenone mechanism of action: a non‑steroidal mineralocorticoid receptor antagonist with high MR selectivity, balanced cardiorenal distribution, no active metabolites, and lower hyperkalemia risk vs steroidal MRAs.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.
